Original Paper

Risk Factors of COVID-19 Critical Outcomes in the Eastern Mediterranean Region: Multicountry Retrospective Study

Faris Lami, PhD; Maisa Elfadul, MD; Hiba Rashak, MSc; Mohannad Al Nsour, MSc, MD, PhD; Hashaam Akhtar, PhD; Yousef Khader, ScD; Ahmed M Hussein, MPH; Mariam Naciri, PhD; Sahar Samy, MSc; Yasser Ghaeleb, MSc; Hana Taha, PhD; Alaa Hussein, MBChB; Nameer A Ali, MBChB; Raheem Hussein, MBChB; Aamer Ikram, PhD; Fazal ur Rahman, MAE; Mohammad Mujeeb Khan, PhD; Reema Adam, MAE; Abdulrazaq Yusuf Ahmed, MD; Salma Afifi, MPH

1Department of Community and Family Medicine, University of Baghdad, Baghdad, Iraq
2Public and Tropical Health Programs, Epidemiology and Biostatistics, University of Medical Sciences and Technology, Khartoum, Sudan
3Ministry of Health, Directorate of Public Health, Baghdad, Iraq
4The Eastern Mediterranean Public Health Network, Global Health Development, Amman, Jordan
5Yusra Medical and Dental College, Yusra Institute of Pharmaceutical Sciences, Islamabad, Pakistan
6Faculty of Medicine, Department of Community Medicine, Public Health and Family Medicine, Jordan University of Science and Technology, Amman, Jordan
7Public Health Department, Somali International University, Magadishu, Somalia
8Research Center Biotechnology, Biodiversity and Environment, Laboratory of Biodiversity, Ecology and Genome, Biology Department, Faculty of Sciences, Mohammed V University, Rabat, Morocco
9Communicable Disease Control Department - Preventive Sector, Ministry of Health and Population, Cairo, Egypt
10Yemen Field Epidemiology Training Program, Ministry of Public Health and Population, Sana’a, Yemen
11Department of Basic Medical Sciences, Faculty of Medicine, The Hashemite University, Zarqa, Jordan
12Public Health Department, Ministry of Health, Babel Health Directorate, Babel, Iraq
13Public Health Department, Ministry of Health, Al-Rusafa Health Directorate, Baghdad, Iraq
14National Institute of Health, Islamabad, Pakistan
15Medical Unit 1 Benazir Bhutto Hospital, Rawalpindi Medical University, Rawalpindi, Pakistan
16Infectious Diseases Department, Rawalpindi Medical University, Rawalpindi, Pakistan
17Federal Ministry of Health, Directorate of Emergency and Humanitarian Actions, Khartoum, Sudan
18Ministry of Health, Demartino Hospital, Mogadishu, Somalia
19Ministry of Health and Population, Cairo, Egypt

Corresponding Author:
Maisa Elfadul, MD
Public and Tropical Health Programs
Epidemiology and Biostatistics
University of Medical Sciences and Technology
Airport Avenue
PO Box 12810
Khartoum, 11111
Sudan
Phone: 249 924622759
Fax: 249 183224799
Email: melfadul7@gmail.com

Abstract

Background: The establishment of empirical evidence in the Eastern Mediterranean Region necessitates the implementation of wide-scale studies to describe the demographic, clinical features, and severity profile of patients with COVID-19.

Objective: This study aims to assess the patterns of COVID-19 severity and mortality in seven countries, and to determine the risk factors of COVID-19 severity and mortality.
Methods: This multicountry study was based on a retrospective review of medical records of hospitalized patients confirmed to have COVID-19. This study includes data from Iraq, Pakistan, Sudan, Somalia, Morocco, Egypt, and Yemen. All demographic and clinical data were extracted from hospital records (paper files) by trained data collectors.

Results: A total of 4141 patients were included in this study from seven countries. Comorbidities were reported by nearly half of the patients, with hypertension (n=1021, 24.7%) and diabetes (n=939, 22.7%) being the most common. Older age, diabetes mellitus, hypertension, and heart diseases were significantly associated with COVID-19 severity and mortality. Ever smoking and renal diseases were significantly associated with severity but not mortality, while male gender, respiratory diseases, and malignancy were significantly associated with mortality but not severity.

Conclusions: The study confirms the role of comorbidities and demographic features on the severity and mortality of COVID-19. Understanding the contributing factors ensures attentive care and informs clinical management of patients with poorer prognoses in the early stages of diseases.

(JMIR Public Health Surveill 2022;8(3):e32831) doi: 10.2196/32831

KEYWORDS

Critical outcomes; COVID-19; severity; mortality; outcome; risk factor; retrospective; implementation; demographic; pattern; trend; risk

Introduction

On December 31, 2019, cases of pneumonia of unknown etiology were reported from Wuhan City, Hubei Province of China [1]. Later, SARS-CoV-2 was identified as a causative agent, and the disease was named COVID-19. The World Health Organization (WHO) declared SARS-CoV-2 to be a global pandemic on March 11, 2020 [1,2]. Globally, 200,840,180 cases of COVID-19 were confirmed and 4,265,903 deaths were reported as of August 6, 2021. In the Eastern Mediterranean Region (EMR), a total of 12,949,856 cases and 240,395 deaths were reported as of August 6, 2021 [3]. The recent forecasting by Institute for Health Metrics and Evaluation has projected COVID-19–related deaths in North Africa and the Middle East to reach up to 327,956 deaths by December 2021 [4].

As many of the countries in the region are experiencing war and political instability, cases and deaths are underreported because of inadequate testing facilities, weak health system response, and inadequate vital registration and documentation [5]. The high hospital admissions and poor surge capacity of critical care were experienced as one of the key health facility challenges that would undermine the response to the COVID-19 pandemic [5]. Difficulties in the estimation of COVID-19 hospital admission rates were highlighted early during the pandemic, as it depends on community testing and admission criteria, which vary between countries. Studies from China, Europe, and the United States have indicated rates of admission to intensive care ranging from 5% to 32%, respectively [6-9].

A recent report showed that Iran has accumulated the highest number of cumulative deaths (n=85,694, case-fatality rate [CFR] 2.6%), followed by Pakistan (n=22,582, CFR 2.3%) and Iraq (n=17,515, CFR 1.2%) [10]. Whereas, Yemen reported the highest CFR (19.7%) followed by Sudan (7.5%). The lowest CFR was reported from Qatar (0.2%) [10]. The difference in the population profile and health system capacity between countries might result in variation in epidemiological characteristics and clinical outcomes. It is worth noting that the Middle East region has a high prevalence of diabetes and cardiovascular diseases (CVDs) that may contribute to heighten the severity of the disease resulting in high mortality and lifelong disability [11-13].

Severe cases of COVID-19 are more likely to deteriorate to conditions that necessitate vital and timely care [6,7]. Epidemiological studies in China, Canada, the United States, and the United Kingdom have identified risk factors associated with severe cases of COVID-19 that require hospital admission [6-9]. Old age, chronic comorbidities, and male sex have consistently been cited as risk factors associated with COVID-19 severity and increased mortality [14-16]. Other risk factors including chronic obstructive pulmonary disease (COPD) and smoking were reported in other studies [17].

Despite the fact that there is limited evidence on the severity of COVID-19 across the EMR, recent studies from Iraq were consistent with global evidence that old age, male gender, and pre-existing comorbidities were associated with increased mortality among hospitalized patients with COVID-19 [18,19].

The establishment of empirical evidence in the EMR necessitates the implementation of wide-scale studies to describe the demographics, clinical features, and severity profiles of patients with COVID-19. Assessing the risk factors of the severe form of COVID-19 is essential to develop appropriate risk reduction strategies and to plan resources for health care as the pandemic unfolds. Furthermore, it will inform clinical management by predicting clinical outcomes and prognostic markers to facilitate the development of a care pathway for COVID-19 critical care. Thus, this study aims to assess the patterns of COVID-19 severity and mortality in seven countries, and to determine the risk factors of COVID-19 severity and mortality.

Methods

Study Design and Data Sources

This multicountry study was based on a retrospective review of medical records of hospitalized patients confirmed to have COVID-19. This study included data from Iraq, Pakistan, Sudan, Somalia, Morocco, Egypt, and Yemen. All data were extracted from hospital records (paper files) by trained data collectors who used a standardized Kobo collect form for data entry. In
all participating countries, the data collected were for patients admitted to hospitals by October 2020.

In Iraq, data were collected for patients with COVID-19 who were admitted during the period between June 1 and 30, 2020, to any one of the six selected hospitals in Baghdad and one hospital in Babylon. The seven hospitals were selected out of the 10 hospitals that received patients with COVID-19 in Baghdad and Babylon because of the presence of Field Epidemiology Training Program residents who collected the data. In Sudan, the study was limited to Khartoum and Gazira states, as they were the high spots for COVID-19 in the country. The data were collected from the two main secondary isolation centers and two primary isolation centers (all hospital records of patients with a confirmed diagnosis between March 2020 and October 2020 were included). In Morocco, data were collected from the Cheikh Zaid International University Hospital of Rabat City, which was dedicated to the hospitalization of patients with COVID-19. In Egypt, data from El-Agoza Hospital in Giza governorate (a high-risk governorate) were collected between May and June 2020. El-Agoza Hospital was designated for the screening and isolation of patients with COVID-19. In Yemen, data were collected on patients with COVID-19 who were admitted to three main isolation hospitals in Sana’a City. In Pakistan, data were collected from two hospitals in Rawalpindi (Benazir Bhutto Hospital and Holy Family Hospital) and two other hospitals in Islamabad (Pakistan Institute of Medical Sciences and Pakistan Air force Hospital) of cases admitted between February and August. All four hospitals were COVID-19 treatment centers. In Somalia, data of patients admitted between March and August to De-Martino Hospital (the only COVID-19 treatment center in Mogadishu) were collected.

Data Abstraction Form
A standardized data collection tool for all countries was developed and converted to the Kobo Toolbox form. The form consisted of four sections. The first section included patients’ baseline and demographic characteristics (age, gender, smoking history, health care worker [HCW] or not, travel history, and history of contact with patients with confirmed COVID-19). The second section included variables related to clinical history and presentation severity, signs and symptoms, and comorbidities. The third section included severity classification. Section four included outcomes (fully recovered, discharged improved, palliative discharge/disable, and death).

Variable Definitions
WHO guidelines were used to define the history of contact (exposure during the 2 days before and the 14 days after the onset of symptoms) and travel history (history of travel 14 days before symptom onset) [20]. The severity of the disease was classified into mild (upper respiratory disease), moderate (pneumonia but no need for oxygen), severe (pneumonia and need oxygen), and critical (needs intensive care unit admission) [21]. Clinical outcomes were defined as follows: fully recovered (negative polymerase chain reaction [PCR] test before discharge or full resolution of symptoms as noted by the attending physician), discharged improved (no PCR was done before discharge but the patient was discharged based on improvement in the clinical picture), palliative discharge/disable (discharged with long-term disability due to COVID-19), and death. During the analysis, we grouped the first three categories under “survivors” and compared them to the fourth category “death.” Critical outcomes included death, palliative discharge, or disability.

Ethical Considerations
Ethical approval was obtained from the institutional review boards in selected countries, and hospital permissions were sought to access patients’ records. Data were coded to maintain confidentiality. All data files were encrypted and saved in a secure database with limited access to the study team.

Data Management and Analysis
Data were entered and managed using the Kobo Toolbox (a tool developed by the Harvard Humanitarian Initiative to be used for field data collection in challenging environments) and then exported to SPSS version 23 (IBM Corp) for analysis. Data were described using percentages and counts. The differences between percentages were tested using the chi-square test. Two separate multiple logistic regression analyses were conducted to determine factors associated with COVID-19 severity and mortality. The final logistic regression models included significant variables only. A P value less than .05 was considered statistically significant.

Results

Demographic and Relevant Characteristics
A total of 4141 patients were included in this study from seven countries, of which Iraq and Pakistan composed almost 60% of the sample followed by Sudan (n=1011, 24.4%). Almost 38% (n=1571) of patients aged 40-59 years, and male patients constituted 63.8% (n=2641) of the sample. About 14.6% of patients were ever smokers. Almost 4% were HCWs. A history of contact with a patient with COVID-19 was indicated by 40.8% (n=1690) of patients. Table 1 shows the demographic and relevant characteristics of patients.
Table 1. Demographic and relevant background characteristics of patients with COVID-19 (N=4141).

| Variables                                      | Patients, n (%) |
|------------------------------------------------|-----------------|
| **Country**                                   |                 |
| Iraq                                          | 1438 (34.7)     |
| Pakistan                                      | 1199 (29.0)     |
| Sudan                                         | 1011 (24.4)     |
| Somalia                                       | 230 (5.6)       |
| Morocco                                       | 123 (3.0)       |
| Egypt                                         | 71 (1.7)        |
| Yemen                                         | 69 (1.7)        |
| **Age (years)**                               |                 |
| <40                                           | 1193 (28.8)     |
| 40-59                                         | 1571 (37.9)     |
| ≥60                                           | 1377 (33.3)     |
| **Sex**                                       |                 |
| Male                                          | 2641 (63.8)     |
| Female                                        | 1500 (36.2)     |
| **Profession**                                |                 |
| Non–health care workers                       | 3994 (96.5)     |
| Health care workers                           | 147 (3.5)       |
| **History of contact with patient with COVID-19 (yes)** | 1690 (40.8) |
| **Smoking**                                   |                 |
| Never                                         | 3537 (85.4)     |
| Ever                                          | 604 (14.6)      |

Comorbidities and Clinical Manifestations

The most common symptoms on admission were fever (n=3198, 77.2%), followed by cough (n=3009, 72.7%) and shortness of breath (n=2224, 53.7%). Other common clusters encompassing musculoskeletal symptoms (myalgia or arthralgia, or backache or fatigue) were reported by 37.6% (n=1557) of patients. A cluster of enteric symptoms was less common in this study (n=398, 9.6%). Comorbidities were reported by nearly half of patients, with hypertension being the most common comorbidity (n=1021, 24.7%), followed by diabetes (n=939, 22.7%). Multiple comorbidities were also reported in almost half of the patients (n=2153, 52%; Table 2).
Table 2. Distribution of study participants by clinical manifestations and comorbidities (N=4141).

| Variables                                                                 | Patients, n (%) |
|--------------------------------------------------------------------------|-----------------|
| **Comorbidities**                                                        |                 |
| No comorbidity                                                           | 2408 (48.2)     |
| Hypertension                                                             | 1021 (24.7)     |
| Diabetes mellitus                                                        | 939 (22.7)      |
| Heart diseases                                                           | 303 (7.3)       |
| Renal disease                                                            | 140 (3.4)       |
| Asthma                                                                   | 111 (2.7)       |
| Respiratory diseases (COPD<sup>a</sup> and other respiratory diseases)   | 61 (1.5)        |
| Malignancy                                                               | 62 (1.5)        |
| Immune compromising conditions                                           | 45 (1.1)        |
| Liver disease                                                            | 22 (0.5)        |
| **Symptoms**                                                             |                 |
| Asymptomatic                                                             | 124 (3.0)       |
| Fever                                                                    | 3198 (77.2)     |
| Cough                                                                    | 3009 (72.7)     |
| Shortness of breath                                                      | 2224 (53.7)     |
| Musculoskeletal manifestations                                           | 1557 (37.6)     |
| Sore throat                                                              | 683 (16.5)      |
| Headache                                                                 | 664 (16.0)      |
| Loss of taste or smell                                                   | 474 (11.4)      |
| Chest pain                                                               | 458 (11.1)      |
| Gastrointestinal or gastroenteric symptoms (nausea/vomiting/diarrhea/abdominal pain) | 364 (8.8)      |
| Sputum production                                                        | 156 (3.8)       |
| Nasal congestion                                                         | 118 (2.8)       |
| Conjunctival congestion                                                  | 37 (0.9)        |
| Hemoptysis                                                               | 36 (0.9)        |
| Other symptoms                                                           | 134 (3.2)       |

<sup>a</sup>COPD: chronic obstructive pulmonary disease.

**Factors Associated With COVID-19 Severity and Mortality**

Of all patients, 27.6% (n=1143) had mild disease, 22.7% (n=940) had moderate disease, 28.9% (n=1197) had severe disease, and 20.7% (n=857) had critical disease. The bivariate analysis had shown that increased age, non–health professions, ever smoking, and comorbidity history, particularly hypertension, diabetes mellitus, heart diseases, and respiratory diseases, were significantly associated with severe or critical COVID-19. Whereas mortality was consistently associated with the aforementioned factors in addition to the male sex, cerebrovascular disease, and malignancy (Table 3).
Table 3. Bivariate analysis of factors associated with COVID-19 severity and mortality.

| Variable                                      | Severity                  |  | Mortality                |  |
|-----------------------------------------------|---------------------------|---|--------------------------|---|
|                                               | Mild-moderate, n (%)      | Severe-critical, n (%) | P value | Survivors, n (%) | Deaths, n (%) | P value |
| **Sex**                                       |                           |                            |         |                |                |         |
| Male                                          | 1318 (49.9)               | 1323 (50.1)                | .45     | 2132 (80.7)   | 509 (19.3)    | .005    |
| Female                                        | 767 (51.1)                | 733 (48.9)                 |         | 1263 (84.2)   | 237 (15.8)    |         |
| **Age (years)**                               |                           |                            |         |                |                |         |
| <40                                           | 849 (71.2)                | 344 (28.8)                 | <.001   | 1115 (93.5)   | 78 (6.5)      | <.001   |
| 40-59                                         | 779 (49.6)                | 792 (50.4)                 |         | 1334 (84.9)   | 237 (15.1)    |         |
| ≥60                                           | 457 (33.2)                | 920 (66.8)                 | <.001   | 946 (68.7)    | 431 (31.3)    |         |
| **Working in health care setting**            |                           |                            |         |                |                |         |
| Non–health care workers                       | 1965 (49.2)               | 2029 (50.8)                | <.001   | 3254 (81.5)   | 740 (18.5)    | <.001   |
| Health care workers                           | 120 (81.6)                | 27 (18.4)                  |         | 141 (95.9)    | 6 (4.1)       |         |
| **Positive history of contact with patient with COVID-19** | 1116 (66.0)               | 574 (34.0)                 | <.001   | 1456 (86.2)   | 234 (13.8)    | <.001   |
| **Smoking**                                   |                           |                            |         |                |                |         |
| Ever                                          | 228 (37.7)                | 376 (62.3)                 | <.001   | 486 (80.5)    | 118 (19.5)    | .29     |
| Never                                         | 1857 (52.5)               | 1680 (47.5)                |         | 2909 (82.2)   | 628 (17.8)    |         |
| **Comorbidities**                             |                           |                            |         |                |                |         |
| Hypertension                                  | 353 (34.6)                | 668 (65.4)                 | <.001   | 714 (69.9)    | 307 (30.1)    | <.001   |
| Diabetes mellitus                             | 319 (34.0)                | 620 (66.0)                 | <.001   | 650 (69.2)    | 289 (30.8)    | <.001   |
| Heart diseases                                | 91 (30.0)                 | 212 (70.0)                 | <.001   | 190 (62.7)    | 113 (37.3)    | <.001   |
| Renal disease                                 | 25 (17.9)                 | 115 (82.1)                 | <.001   | 108 (77.1)    | 32 (22.9)     | .13     |
| Asthma                                        | 50 (45.0)                 | 61 (55.0)                  | .26     | 91 (82.0)     | 20 (18.0)     | >.99    |
| Respiratory diseases                          | 21 (34.4)                 | 40 (65.6)                  | .01     | 38 (62.3)     | 23 (37.7)     | <.001   |
| Malignancy                                    | 21 (33.9)                 | 41 (66.1)                  | .009    | 43 (69.4)     | 19 (30.6)     | .009    |
| Immunocompromising conditions                 | 12 (26.7)                 | 33 (73.3)                  | <.001   | 39 (86.7)     | 6 (13.3)      | .41     |
| Liver disease                                 | 8 (36.4)                  | 14 (63.6)                  | .19     | 16 (72.7)     | 6 (27.3)      | .26     |
| Tuberculosis                                  | 19 (33.9)                 | 37 (66.1)                  | .01     | 42 (75.0)     | 14 (25.0)     | .17     |
| Cerebrovascular disease                       | 8 (42.1)                  | 11 (57.9)                  | .47     | 12 (63.2)     | 7 (36.8)      | .03     |

The multiple logistic regression indicated that increased age and smoking were significantly associated with severity ($P<.001$). Patients older than 60 years were three times more likely to develop a severe or critical form of COVID-19 compared to patients younger than 40 years. Patients with smoking history were 10 times more likely to develop severe or critical disease course compared to nonsmokers (odds ratio [OR] 9.7, 95% CI 5.1-18.5; $P<.001$). Not having a history of contact with patients with COVID-19 (OR 2.8, 95% CI 2.4-3.2; $P<.001$) and being non-HCWs (OR 2, 95% CI 1.2-3.1; $P=.004$) were also significantly associated with developing a severe form of COVID-19. Of comorbidities, renal diseases (OR 3.3, 95% CI 2.1-5.2; $P<.001$), heart diseases (OR 1.7, 95% CI 1.3-2.2; $P<.001$), diabetes (OR 1.4, 95% CI 1.2-1.7; $P<.001$), and hypertension (OR 1.2, 95% CI 1-1.5; $P=.03$) were associated with increased odds of severe disease (Table 4).
Table 4. Multiple logistic regression of factors associated with COVID-19 severity and mortality.

| Covariates                        | Factors associated with COVID-19 severity | Factors associated with COVID-19 mortality |
|-----------------------------------|------------------------------------------|------------------------------------------|
| Sex (female vs male)              | N/A                                      | 0.8 (0.7-1)                              |
| Age (years)                       |                                          | .02                                       |
| <40 (reference)                   | N/A                                      | N/A                                      |
| 40-59                             | 2 (1.7-2.4)                              | 1.9 (1.5-2.5)                            |
| ≥60                               | 3.1 (2.6-3.8)                            | 4 (3.1-5.3)                              |
| Profession                        |                                          |                                          |
| Health care workers (reference)   | N/A                                      | N/A                                      |
| Non–health care workers           | 2 (1.2-3.1)                              | 2.4 (1.5-6)                              |
| History of contact with COVID-19 (no vs yes) |                          | .04                                       |
| Diabetes mellitus (yes vs no)     | 1.4 (1.2-1.7)                            | 1.6 (1.3-1.9)                            |
| Hypertension (yes vs no)          | 1.2 (1-1.5)                              | 1.3 (1.1-1.6)                            |
| Heart diseases (yes vs no)        | 1.7 (1.3-2.2)                            | 1.8 (1.4-2.3)                            |
| Renal disease (yes vs no)         | 3.3 (2.1-5.2)                            | <.001                                    |
| Respiratory diseases (yes vs no)  | —                                        | 2.1 (1.2-3.7)                            |
| Malignancy (yes vs no)            | —                                        | 1.8 (1-3.3)                              |
| Symptomatic (yes vs no)           | —                                        | 4.5 (1.6-12.6)                           |
| Smoking (ever vs never)           | 9.7 (5.1-18.5)                           | <.001                                    |

aOR: odds ratio.
bNot entered in the model because the variable was not statistically significant.
cN/A: not applicable.

Increasing age was a strong predictor of mortality in hospitals, as the older age group (>60 years) was associated with an increased odds of death by almost four times compared to the younger age category (OR 4, 95% CI 3.1-5.3; P<.001). The history of contact with patients with COVID-19 and being a non–HCW had higher odds of mortality. Female sex was associated with lower odds of mortality (OR 0.8, 95% CI 0.7-1.0; P=.02). Comorbidities associated with high odds of mortality included respiratory diseases (OR 2.1, 95% CI 1.2-3.7; P=.009), heart diseases (OR 1.8, 95% CI 1.4-2.3; P<.001), malignancy (OR 1.8, 95% CI 1.0-3.3; P=.04), and diabetes mellitus (OR 1.6, 95% CI 1.3-1.9; P<.001). Renal diseases and smoking history had no significant association with mortality (Table 4).

Discussion

Principal Results

The data of a cohort of patients with COVID-19 hospitalized in seven different countries were collected and analyzed. The proportion of hospitalized patients with severe or critical illness in this study (49.6%) is remarkably higher than what is being reported from other parts of the world on hospitalized patients with COVID-19 [22-25]. To our knowledge, only one study from Wuhan reported a severity profile as high as 49.1% [26]. However, given that the study was conducted among hospitalized patients rather than in the community, these proportions are not a true representative of the COVID-19 severity spectrum in this region. At the beginning of the pandemic, the health care facilities used to admit patients with COVID-19 of different severity for the sake of isolation and treatment of those patients. Later, with the increase in the number of patients, the health care facilities in most of these countries started to reserve the already limited hospital beds to treat the more severe cases, which in turn shifted the majority of mild/moderate cases to be treated at home.

We found older age, diabetes mellitus, hypertension, and heart diseases to be associated with both severity and mortality. Furthermore, ever smoking and renal diseases were associated with severity but not mortality, while male gender, respiratory diseases (COPD or other respiratory diseases), and malignancy were associated with mortality but not severity. The latter category is of special importance, given the fact that these patients might die even if they do not experience severe or critical illness. The majority of these findings are consistent with previous studies on COVID-19 severity or mortality [27-31].

What Is Already Known on This Topic

Unraveling the pathophysiology of COVID-19 is still a work in progress. Nevertheless, the role of angiotensin-converting enzyme 2 (ACE2) receptors is widely recognized as a key player in the disease process. ACE2 is a metallopeptidase that is expressed in various human organs [32] and is thought to be the cell entry point for SARS-CoV-2 [33]. Among others, it has been found on cell membranes of the nasal epithelium, alveolar
epithelial cells of the lungs, the small intestine enterocytes, vascular endothelial cells, and cardiovascular system cells [32-35]. It is believed that negative regulation of the renin-angiotensin system (RAS) is a main function of ACE2. RAS has been linked to lung injury [36,37], which has led to concluding that ACE2 has a protective effect on the lungs [38,39] and that its pre-existing deficiency might lead to a more severe or even fatal COVID-19 [40].

Older patients, males, and patients with type 2 diabetes mellitus were frequently found to have severe or fatal COVID-19 in epidemiological studies. Interestingly, they were also found to have lower ACE2 expression, which might help explain why they are disproportionately affected by poor COVID-19 outcomes [41-43]. Furthermore, age (the earliest and most widely recognized predictor of COVID-19 severity and mortality) showed the strongest correlation with low ACE2 expression [41].

In addition to ACE2 downregulation, other biological and nonbiological factors might help explain some of our findings. For example, differences in the biological and molecular level in older patients (as compared to younger ones) might have their contribution to the disease course [44]. In particular, two cardinal features of the aging immune system are probably the culprits: immune senescence (a general decline in the overall performance of the immune system, innate and acquired) and inflamm-aging (a systemwide persistent proinflammatory status) [44-46]. However, some have argued that age-associated comorbidities, rather than age itself, are the major factor behind these findings [47]. However, in this paper, we found that age is an independent risk factor on top of the comorbidities from the multiple logistic regression (Table 4).

Diabetes mellitus is another risk factor where the dysregulated immune response is thought to play a role in a patient’s susceptibility to critical COVID-19 outcomes. Similar to aging, patients with diabetes are in a state of low-grade chronic inflammation [48]. Furthermore, diabetes is associated with reduced activity of natural killer cells and impaired cell-mediated adaptive immunity (chemotaxis, phagocytosis, cytokine secretion, and T-cell abnormalities) [48].

The fact that an overactive RAS is a key aspect of the pathogenesis of CVD (heart diseases and hypertension) [49,50] might explain the association between CVD and fatal COVID-19. An already existing abnormal cytokine profile in patients with these comorbidities can be part of the explanation as well [51-53]. Knowing that cytokine storm is frequently linked to severe and fatal COVID-19 strengthens the biological plausibility of this explanation [8,54].

Similar to CVD, some renal diseases are characterized by an overactive RAS [55] and linked to dysregulated cytokine function and proinflammatory status [56,57]. Although patients with renal diseases were more likely to have severe illness in our study, we found no association with mortality. This is inconsistent with previous reports [58,59], which might be explained by differences in renal disease definitions and severity levels of the studied patients. These same reasons might explain why, unlike other studies [60], we found no association between liver disease and critical COVID-19 outcomes.

The defective local physiological function of the respiratory system in patients with COPD and other respiratory diseases could explain their predisposition to worse COVID-19 outcomes. Conversely, asthma was not associated with COVID-19 severity or mortality. The evidence in the literature on asthma has been inconclusive [61].

Comparison With Prior Work

Despite the fact that smoking is probably underestimated in our study due to associated stigma, particularly among women, we were able to find an association with severity. However, this same underestimation might be the reason why, unlike previous reports [17], we could not find an association with mortality. Another reason is the fact that in our study, due to small cell size, we combined former and current smokers under the same category, while in other studies, mortality was found to be associated with current rather than former smokers [17].

Unexpectedly, we also found not working in a health care setting and not having a history of contact with a known COVID-19 case to be associated with both severity and mortality. These findings should be interpreted with caution though; patients with a known COVID-19 contact history might be better informed and more likely to seek help early and thus less likely to have critical outcomes.

There is also the possibility that the history of contact is underreported mainly for two reasons. First, the stigma around the disease may prevent many people from telling everyone around them; thus, many people may not realize that they had been in contact with a patient with COVID-19.

Second, the societies in the EMR are among the most social in the world and being friendly to strangers is the social norm. In Iraq, for example, religious mass gatherings where strangers often socialize without observing social distancing is a frequent occurrence. There is a decent possibility that some of the patients in this study might, unknowingly, had come in contact with symptomatic or mild COVID-19 cases during one of these events.

Similar to our study, a meta-analysis by the American Journal of Emergency Medicine [62] found that HCWs were less likely to have severe or critical disease, or to die of COVID-19. The proposed explanation by the authors seems to hold for our study as well: that HCWs tend to come from a younger age cohort, have lower rates of smoking and obesity, and not having a history of contact with a known COVID-19 patient. The defective local physiological function of the respiratory system in patients with COPD and other respiratory diseases could explain their predisposition to worse COVID-19 outcomes. Conversely, asthma was not associated with COVID-19 severity or mortality. The evidence in the literature on asthma has been inconclusive [61].

What This Study Adds

Almost a year has passed since the COVID-19 pandemic started, and still the best intervention we have to fight it with is nonpharmaceutical measures. There is no definite treatment to date, and although good news on effective vaccines is emerging, it might take a few years until enough of the population has access to a vaccine. That is why, in the hospital setting, it is still imperative to identify which patients are at higher risk of...
developing severe disease or dying of COVID-19. Although many studies reported on this worldwide, to our best knowledge, this is the first large multicenter study coming out of the EMR.

**Limitations**

This study has its limitations. First, the study was conducted in a hospital setting, which limits our ability to generalize our findings to the general population. Second, given that in many hospitals in the selected countries hospital admissions were reserved for the most severe cases, our study might be biased toward more severe outcomes. Finally, some variables might be underreported due to the inability of the HCWs in the overwhelmed facilities to collect all data for all patients.

**Conclusions**

This study reports on risk factors of COVID-19 severity and mortality in the seven countries. In a hospital setting, health care providers should be more attentive to older patients, men, smokers, and patients with certain comorbidities (diabetes, hypertension, heart diseases, COPD, malignancy, and renal diseases), as they were shown to be more likely to have severe or fatal COVID-19 in our study.

**Acknowledgments**

The authors would like to thank the Global Health Development (Eastern Mediterranean Public Health Network for their support. The authors would also like to thank Dr Abdelaziz Barkia (Epidemic Diseases Service, Ministry of Health of Morocco); Dr Younes Zaid (associate professor at Mohammed V University in Rabat, Morocco); Mariam Laatifi (PhD student, Mohammed V University in Rabat, Morocco); Hind Ezzine (PhD student, Mohammed V University in Rabat, Morocco); Alaa Eid, MD (Ministry of Health and Population, Cairo, Egypt); Ehab Kamal, MD (Ministry of Health and Population, Cairo, Egypt); Mohamed Hassany, MD (Ministry of Health and Population, Cairo, Egypt); Hanaa Abu El Sood, MPH (Ministry of Health and Population, Cairo, Egypt); and Dr Anwar Ahmed (ER consultant, Ministry of Health, Sudan).

**Conflicts of Interest**

None declared.

**References**

1. COVID-19 - China. World Health Organization. 2020 Jan 05. URL: [https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON229](https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON229) [accessed 2021-08-10]

2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020 Feb 22;395(10224):565-574 [FREE Full text] [doi: 10.1016/S0140-6736(20)30251-8] [Medline: 3207145]

3. WHO Coronavirus (COVID-19) Dashboard. World Health Organization. URL: [https://covid19.who.int](https://covid19.who.int) [accessed 2020-11-28]

4. COVID-19 Projections. URL: [https://covid19.healthdata.org/](https://covid19.healthdata.org/) [accessed 2021-08-11]

5. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA 2020 Apr 28;323(16):1545-1546. [doi: 10.1001/jama.2020.4031] [Medline: 32167538]

6. Kaplan LJ, Kleinpell R, Maves RC, Doersam JK, Raman R, Ferraro DM. Critical care clinician reports on coronavirus disease 2019: results from a national survey of 4,875 ICU providers. Crit Care Explor 2020 May;2(5):e0125 [FREE Full text] [doi: 10.1097/CCE.0000000000000125] [Medline: 32671350]

7. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020 Jun;20(6):669-677 [FREE Full text] [doi: 10.1016/S1473-3099(20)30243-7] [Medline: 32167538]

8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020 Feb 15;395(10223):497-506 [FREE Full text] [doi: 10.1016/S0140-6736(20)30183-5] [Medline: 31986264]

9. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020 Apr 30;382(18):1708-1720 [FREE Full text] [doi: 10.1056/NEJMoa2002032] [Medline: 32109013]

10. WHO EMRO COVID-19 situation updates week 27 (4–10 July 2021). ReliefWeb. URL: [https://reliefweb.int/report/iran-islamic-republic/who-emro-covid-19-situation-updates-week-27-4-10-july-2021](https://reliefweb.int/report/iran-islamic-republic/who-emro-covid-19-situation-updates-week-27-4-10-july-2021) [accessed 2021-08-10]

11. Dil S, Dil N, Maken Z. COVID-19 trends and forecast in the Eastern Mediterranean Region with a particular focus on Pakistan. Cureus 2020 Jun 12;12(6):e8582 [FREE Full text] [doi: 10.7759/cureus.8582] [Medline: 32670717]

12. Abuysassim B, Laher I. Diabetes epidemic sweeping the Arab world. World J Diabetes 2016 Apr 25;7(8):165-174 [FREE Full text] [doi: 10.4239/wjd.v7.i8.165] [Medline: 27114755]

13. Raafl FJ, Alsheikh-Ali AA, Omar MI, Rashed W, Hamou O, Kame A, et al. Cardiovascular risk factor burden in Africa and the Middle East across country income categories: a post hoc analysis of the cross-sectional Africa Middle East Cardiovascular Epidemiological (ACE) study. Arch Public Health 2018;76:15 [FREE Full text] [doi: 10.1186/s13690-018-0257-5] [Medline: 29449941]
14. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, the Northwell COVID-19 Research Consortium, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 2020 May 26;323(20):2052-2059 [FREE Full text] [doi: 10.1001/jama.2020.6775] [Medline: 32320003]

15. Jin J, Bai P, He W, Wu F, Liu X, Han D, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health 2020;8:152. [doi: 10.3389/fpubh.2020.00152] [Medline: 32411652]

16. Leiva Sisnieguez CE, Espeche WG, Salazar MR. Arterial hypertension and the risk of severity and mortality of COVID-19. Eur Respir J 2020 Jun;55(6):2001148 [FREE Full text] [doi: 10.1183/13993003.01148-2020] [Medline: 32398296]

17. Alqahtani JS, Oyelade T, Aldhahri AM, Alghamdi M, Alqahtani AS, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One 2020;15(5):e0233147 [doi: 10.1371/journal.pone.0233147] [Medline: 32392262]

18. Alhilfi RA, Majeed YY, Banooah AK, Ali SS, Shnan BA, Muftin AB. Epidemiological characteristics of confirmed COVID-19 cases in Iraq, three months situation analysis. Iraqi N Med J 2020;6(12):1.

19. Alhilfi RA, Majeed YY, Banooah AK, Ali SS, Shnan BA, Muftin AB. Death from COVID-19 in Iraq, and its associated risk factor: a three-month situation analysis. Iraqi N Med J 2020;6(12):93 [FREE Full text]

20. Global surveillance for COVID-19 caused by human infection with COVID-19 virus: interim guidance, 20 March 2020. World Health Organization. URL: https://apps.who.int/iris/handle/10665/331506 [accessed 2022-02-15]

21. Clinical management of COVID-19: interim guidance, 27 May 2020. World Health Organization. URL: https://apps.who.int/iris/handle/10665/332196 [accessed 2022-02-15]

22. Yao Q, Wang P, Wang X, Qie G, Meng M, Tong X, et al. A retrospective study of risk factors for severe acute respiratory syndrome coronavirus 2 infections in hospitalized adult patients. Pol Arch Intern Med 2020 May 29;130(5):390-399 [FREE Full text] [doi: 10.20452/pamw.15312] [Medline: 32329978]

23. Zhang S, Lian J, Hu J, Zhang X, Lu Y, Cai H, et al. Clinical characteristics of different subtypes and risk factors for the severity of illness in patients with COVID-19 in Zhejiang, China. Infect Dis Poverty 2020 Jul 08;9(1):85 [FREE Full text] [doi: 10.1186/s40249-020-00710-6] [Medline: 32641211]

24. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020 Jun 06;395(10239):1763-1770 [FREE Full text] [doi: 10.1016/S0140-6736(20)31189-2] [Medline: 32442528]

25. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020 Apr 07;323(13):1239-1242. [doi: 10.1001/jama.2020.2648] [Medline: 32091533]

26. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020 Jul;146(1):110-118 [FREE Full text] [doi: 10.1016/j.jaci.2020.04.006] [Medline: 32294485]

27. Kumar A, Arora A, Sharma P, Anikhindra SA, Bansal N, Singla V, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr 2020;14(4):535-545 [FREE Full text] [doi: 10.1016/j.dsx.2020.04.044] [Medline: 32388818]

28. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. J Infect 2020 Aug;81(2):e16-e25 [FREE Full text] [doi: 10.1016/j.jinf.2020.04.021] [Medline: 32335169]

29. Nandy K, Salunke A, Pathak SK, Pandey A, Doctor C, Puj K, et al. Coronavirus disease (COVID-19): a systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events. Diabetes Metab Syndr 2020;14(5):1017-1025 [FREE Full text] [doi: 10.1016/j.dsx.2020.06.064] [Medline: 32634716]

30. Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: a systematic review and meta-analysis. Int J Infect Dis 2020 Oct;99:47-56 [FREE Full text] [doi: 10.1016/j.ijid.2020.07.029] [Medline: 32721533]

31. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY) 2020 Apr 08;12(7):6049-6057 [FREE Full text] [doi: 10.18632/aging.103000] [Medline: 32267833]

32. Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004 Jun;203(2):631-637 [FREE Full text] [doi: 10.1002/path.1570] [Medline: 15141377]

33. Parasher A. COVID-19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J 2021 May;97(1147):312-320. [doi: 10.1136/postgradmedj-2020-138577] [Medline: 32978337]

34. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotsin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circulation 2001;103(5):E1-E9. [Medline: 10.1161/01.res.87.5.e1] [Medline: 10969042]

35. Harmer D, Gilbert M, Borman R, Clark K. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotsin converting enzyme. FEBS Lett 2002 Dec 04;532(1-2):107-110 [FREE Full text] [doi: 10.1016/s0014-5793(02)03640-2] [Medline: 12459472]
36. Marshall RP, Gohlke P, Chambers RC, Howell DC, Bottoms SE, Unger T, et al. Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004 Jan;286(1):L156-L164 [FREE Full text] [doi: 10.1152/ajplung.00313.2002] [Medline: 12754187]

37. Imai Y, Kuba K, Penninger JM. The renin-angiotensin system in acute respiratory distress syndrome. Drug Discov Today Dis Mech 2006;3(2):225-229 [FREE Full text] [doi: 10.1016/j.ddmech.2006.06.012] [Medline: 16109138]

38. Samavati L, Uhal BD. ACE2, much more than just a receptor for SARS-CoV-2. Front Cell Infect Microbiol 2020;10:317. [doi: 10.3389/fcimb.2020.00317] [Medline: 32582574]

39. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005 Jul 07;436(7047):112-116 [FREE Full text] [doi: 10.1038/nature03712] [Medline: 16001071]

40. Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med 2020 Jun;76:14-20 [FREE Full text] [doi: 10.1016/j.ejim.2020.04.037] [Medline: 32336612]

41. Chen J, Jiang Q, Xia X, Liu K, Yu Z, Tao W, et al. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. Aging Cell 2020 Jul;19(7):e13168. [doi: 10.1111/acel.13168] [Medline: 32558150]

42. Arnold RH. COVID-19 - does this disease kill due to imbalance of the renin angiotensin system (RAS) caused by genetic and gender differences in the response to viral ACE 2 attack? Heart Lung Circ 2020 Jul;29(7):964-972 [FREE Full text] [doi: 10.1016/j.hlc.2020.05.004] [Medline: 32654908]

43. Xie X, Xudong X, Chen J, Junzhu C, Wang X, Xingxiang W, et al. Age- and gender-related difference of ACE2 expression in rat lung. Life Sci 2006 Apr 04;78(19):2166-2171 [FREE Full text] [doi: 10.1016/j.lfs.2005.09.038] [Medline: 16303146]

44. Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging (Albany NY) 2020 May 29;12(10):9959-9981 [FREE Full text] [doi: 10.18632/aging.103344] [Medline: 32470948]

45. Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann NY Acad Sci 2000 Jun;908:244-254. [doi: 10.1111/j.1749-6632.2000.tb06651.x] [Medline: 10919163]

46. Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev 2020 Jun;53:33-37 [FREE Full text] [doi: 10.1016/j.cytogfr.2020.04.002] [Medline: 32389499]

47. Romero Starke K, Petereit-Haack G, Schubert M, Kämpf D, Schliebner A, Hegewald J, et al. The age-related risk of severe outcomes due to COVID-19 infection: a rapid review, meta-analysis, and meta-regression. Int J Environ Res Public Health 2020 Aug 17;17(16):5974 [FREE Full text] [doi: 10.3390/ijerph17165974] [Medline: 32824596]

48. Erenre S. Diabetes, infection risk and COVID-19. Mol Metab 2020 Sep;39:101044 [FREE Full text] [doi: 10.1016/j.molmet.2020.10.044] [Medline: 32585364]

49. Takimoto-Ohnishi E, Murakami K. Renin-angiotensin system research: from molecules to the whole body. J Physiol Sci 2019 Jul;69(4):581-587. [doi: 10.1007/s12376-019-00679-4] [Medline: 31028527]

50. Ferrario CM, Strawn WB. Role of the renin-angiotensin aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006 Jul 01;98(1):121-128. [doi: 10.1016/j.amjcard.2006.01.059] [Medline: 16784934]

51. Mehra VC, Ramgolam VS, Bender JR. Cytokines and cardiovascular disease. J Leukoc Biol 2005 Oct;78(4):805-818. [doi: 10.1189/jlb.0405182] [Medline: 16006537]

52. Tanase D, Gosav E, Radu S, Ouatu A, Rezus C, Ciocoiu M, et al. Arterial hypertension and interleukins: potential therapeutic target or future diagnostic marker? Int J Hypertens 2019;2019:3159283. [doi: 10.1155/2019/3159283] [Medline: 31186952]

53. Huang S, Wang J, Liu F, Liu J, Cao G, Yang C, et al. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertens Res 2020 Aug;43(8):824-831 [FREE Full text] [doi: 10.1038/s41440-020-0485-2] [Medline: 32483331]

54. Ragab D, Salah Eldin H, Taemah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol 2020;11:1446. [doi: 10.3389/fimmu.2020.01446] [Medline: 32612617]

55. Rüster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006 Nov;17(11):2985-2991 [FREE Full text] [doi: 10.1681/ASN.2006040556] [Medline: 17035613]

56. Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel P. Cytokine dysregulation in chronic kidney disease: how can we treat it? Blood Purif 2008;26(3):291-299 [FREE Full text] [doi: 10.1159/000126926] [Medline: 18421214]

57. Mihai S, Codrici E, Popescu ID, Enciu A, Albulescu L, Necula LG, et al. Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. J Immunol Res 2018;2018:2180373. [doi: 10.1155/2018/2180373] [Medline: 30271792]

58. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFEELY. Nature 2020 Aug;584(7821):430-436 [FREE Full text] [doi: 10.1038/s41586-020-2521-4] [Medline: 32640463]

59. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Int J Obs 2020 May;97(5):829-838 [FREE Full text] [doi: 10.1016/j.ij.kint.2020.03.005] [Medline: 32247631]
60. Oyelade T, Alqahtani J, Canciani G. Prognosis of COVID-19 in patients with liver and kidney diseases: an early systematic review and meta-analysis. Trop Med Infect Dis 2020 May 15;5(2):80 [FREE Full text] [doi: 10.3390/tropicalmed5020080] [Medline: 32429038]

61. Hartmann-Boyce J, Gunnell J, Drake J, Otunla A, Suklan J, Schofield E, et al. Asthma and COVID-19: review of evidence on risks and management considerations. BMJ Evid Based Med 2020 Sep 03;bmjebm-2020-111506. [doi: 10.1136/bmjebm-2020-111506] [Medline: 32883705]

62. Sahu AK, Amrithanand V, Mathew R, Aggarwal P, Nayer J, Bhoi S. COVID-19 in health care workers - a systematic review and meta-analysis. Am J Emerg Med 2020 Sep;38(9):1727-1731 [FREE Full text] [doi: 10.1016/j.ajem.2020.05.113] [Medline: 32738467]

63. Characteristics of health care personnel with COVID-19 — United States, February 12–April 9, 2020. Centers for Disease Control and Prevention. 2020. URL: https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e6.htm [accessed 2021-01-03]

Abbreviations

ACE2: angiotensin-converting enzyme 2
CFR: case-fatality rate
COPD: chronic obstructive pulmonary disease
CVD: cardiovascular disease
EMR: Eastern Mediterranean Region
HCW: health care worker
OR: odds ratio
PCR: polymerase chain reaction
RAS: renin-angiotensin system
WHO: World Health Organization

©Faris Lami, Maisa Elfadul, Hiba Rashak, Mohannad Al Nsour, Hashaam Akhtar, Youself Khader, Ahmed M Hussein, Mariam Naciri, Sahar Samy, Yasser Ghaleb, Hana Taha, Alaa Hussein, Nameer A Ali, Raheem Hussein, Aamer Ikram, Fazal ur Rahman, Mohammad Mugeeb Khan, Reema Adam, Abdulrazaq Yusuf Ahmed, Salma Afifi. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 15.03.2022. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Public Health and Surveillance, is properly cited. The complete bibliographic information, a link to the original publication on https://publichealth.jmir.org, as well as this copyright and license information must be included.